Erasca Raises $225M in Upsized Public Offering of Common Stock

Erasca, a clinical-stage precision oncology company, has announced the pricing of an upsized public offering of 22.5 million shares of common stock at $10.00 per share, raising $225 million in gross proceeds. The company plans to use the funds to fund research and development of its product candidates and for general corporate purposes. The offering is expected to close on January 23, 2026.